PEDIATRICS Vol. 99 No. 6 June 1997, pp. 765-773 (doi:10.1542/peds.99.6.765)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, R. T.
Right arrow Articles by the Vaccine Safety Datalink Team,
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, R. T.
Right arrow Articles by the Vaccine Safety Datalink Team,

PEDIATRICS Vol. 99 No. 6 June 1997, pp. 765-773

Vaccine Safety Datalink Project: A New Tool for Improving Vaccine Safety Monitoring in the United States

Received Apr 1, 1996; accepted Jun 14, 1996.

Robert T. Chen*, John W. Glasser*, Philip H. Rhodes*, Robert L. DavisDagger , William E. BarlowDagger , Robert S. ThompsonDagger , John P. Mullooly§, Steve B. Blackparallel , Henry R. Shinefieldparallel , Connie M. Vadheim, S. Michael Marcy#, Joel I. Ward, Robert P. Wise**, Steven G. Wassilak*, Stephen C. Hadler*, and the Vaccine Safety Datalink Team

From the * National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia; Dagger  Center for Health Studies, Group Health Cooperative of Puget Sound, Seattle, Washington; § Center for Health Research, Northwest Kaiser Permanente, Portland, Oregon; parallel  Pediatric Vaccine Study Center, Northern California Kaiser Permanente, Oakland;  Center for Vaccine Research, Harbor-UCLA Medical Center, Torrance, California; # Southern California Kaiser Permanente, Pasadena; and ** Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland.

Objective.  To fill the large "gaps and limitations" in current scientific knowledge of rare vaccine adverse events identified in recent reviews of the Institute of Medicine.

Methods.  Computerized information on immunization, medical outcomes, and potential confounders on more than 500 000 children 0 to 6 years of age is linked annually at several health maintenance organizations to create a large cohort for multiple epidemiologic studies of vaccine safety.

Results.  Analysis of 3 years of follow-up data shows that 549 488 doses of diphtheria-tetanus-pertussis (DTP) and 310 618 doses of measles-mumps-rubella (MMR) vaccines have been administered to children in the study cohort. Analyses for associations between vaccines and 34 medical outcomes are underway. Screening of automated data shows that seizures are associated with receipt of DTP on the same day (relative risk [RR], 2.1; 95% confidence interval [CI], 1.1 to 4.0) and 8 to 14 days after receipt of MMR (RR, 3.0; 95% CI, 2.1 to 4.2). The diversity of vaccination exposures in this large cohort permits us to show that an apparent association of seizures 8 to 14 days after Haemophilus influenzae type b vaccine (RR, 1.6; 95% CI, 1.2 to 2.1) was attributable to confounding by simultaneous MMR vaccination; the association disappears with appropriate adjustment (RR, 1.0; 95% CI, 0.7 to 1.4).

Conclusion.  Preliminary design, data collection, and analytic capability of the Vaccine Safety Datalink project has been validated by replication of previous known associations between seizures and DTP and MMR vaccines. The diversity in vaccine administration schedules permits potential disentangling of effects of simultaneous and combined vaccinations. The project provides a model of public health-managed care collaborations in addition to an excellent infrastructure for safety and other studies of vaccines.

Key words: vaccines, immunization, adverse reactions, databases, record linkage, vaccine safety.




This article has been cited by other articles:


Home page
PediatricsHome page
M. M. Braun
Toward Better Vaccine Safety Data and Safer Vaccination
Pediatrics, March 1, 2008; 121(3): 625 - 626.
[Full Text] [PDF]


Home page
PediatricsHome page
J. Glanz, E. France, S. Xu, T. Hayes, and S. Hambidge
A Population-Based, Multisite Cohort Study of the Predictors of Chronic Idiopathic Thrombocytopenic Purpura in Children
Pediatrics, March 1, 2008; 121(3): e506 - e512.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
E. K. France, J. Glanz, S. Xu, S. Hambidge, K. Yamasaki, S. B. Black, M. Marcy, J. P. Mullooly, L. A. Jackson, J. Nordin, et al.
Risk of Immune Thrombocytopenic Purpura After Measles-Mumps-Rubella Immunization in Children
Pediatrics, March 1, 2008; 121(3): e687 - e692.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
W. W. Thompson, C. Price, B. Goodson, D. K. Shay, P. Benson, V. L. Hinrichsen, E. Lewis, E. Eriksen, P. Ray, S. M. Marcy, et al.
Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years
N. Engl. J. Med., September 27, 2007; 357(13): 1281 - 1292.
[Abstract] [Full Text] [PDF]


Home page
Arch Pediatr Adolesc MedHome page
E. K. France, R. Smith-Ray, D. McClure, S. Hambidge, S. Xu, K. Yamasaki, D. Shay, E. Weintraub, A. M. Fry, S. B. Black, et al.
Impact of Maternal Influenza Vaccination During Pregnancy on the Incidence of Acute Respiratory Illness Visits Among Infants
Arch Pediatr Adolesc Med, December 1, 2006; 160(12): 1277 - 1283.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
S. J. Hambidge, J. M. Glanz, E. K. France, D. McClure, S. Xu, K. Yamasaki, L. Jackson, J. P. Mullooly, K. M. Zangwill, S. M. Marcy, et al.
Safety of Trivalent Inactivated Influenza Vaccine in Children 6 to 23 Months Old
JAMA, October 25, 2006; 296(16): 1990 - 1997.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
C. W. LeBaron, D. Bi, B. J. Sullivan, C. Beck, and P. Gargiullo
Evaluation of Potentially Common Adverse Events Associated With the First and Second Doses of Measles-Mumps-Rubella Vaccine
Pediatrics, October 1, 2006; 118(4): 1422 - 1430.
[Abstract] [Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
W. A. Orenstein, R. G. Douglas, L. E. Rodewald, and A. R. Hinman
Immunizations In The United States: Success, Structure, And Stress
Health Aff., May 1, 2005; 24(3): 599 - 610.
[Abstract] [Full Text] [PDF]


Home page
Arch Pediatr Adolesc MedHome page
E. K. France, J. M. Glanz, S. Xu, R. L. Davis, S. B. Black, H. R. Shinefield, K. M. Zangwill, S. M. Marcy, J. P. Mullooly, L. A. Jackson, et al.
Safety of the Trivalent Inactivated Influenza Vaccine Among Children: A Population-Based Study
Arch Pediatr Adolesc Med, November 1, 2004; 158(11): 1031 - 1036.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
N. Andrews, E. Miller, A. Grant, J. Stowe, V. Osborne, and B. Taylor
Thimerosal Exposure in Infants and Developmental Disorders: A Retrospective Cohort Study in the United Kingdom Does Not Support a Causal Association
Pediatrics, September 1, 2004; 114(3): 584 - 591.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Public HealthHome page
D. A. Salmon, L. H. Moulton, and N. A. Halsey
Enhancing Public Confidence in Vaccines Through Independent Oversight of Postlicensure Vaccine Safety
Am J Public Health, June 1, 2004; 94(6): 947 - 950.
[Abstract] [Full Text]


Home page
PediatricsHome page
T. Verstraeten, R. L. Davis, F. DeStefano, T. A. Lieu, P. H. Rhodes, S. B. Black, H. Shinefield, R. T. Chen, and for the Vaccine Safety Datalink Team
Safety of Thimerosal-Containing Vaccines: A Two-Phased Study of Computerized Health Maintenance Organization Databases
Pediatrics, November 1, 2003; 112(5): 1039 - 1048.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
N. Le Saux, N. J. Barrowman, D. L. Moore, S. Whiting, D. Scheifele, S. Halperin, and for Members of the Canadian Paediatric Society/ He
Decrease in Hospital Admissions for Febrile Seizures and Reports of Hypotonic-Hyporesponsive Episodes Presenting to Hospital Emergency Departments Since Switching to Acellular Pertussis Vaccine in Canada: A Report From IMPACT
Pediatrics, November 1, 2003; 112(5): e348 - 348.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
T. Verstraeten, A. O. Jumaan, J. P. Mullooly, J. F. Seward, H. S. Izurieta, F. DeStefano, S. B. Black, and R. T. Chen
A Retrospective Cohort Study of the Association of Varicella Vaccine Failure With Asthma, Steroid Use, Age at Vaccination, and Measles-Mumps-Rubella Vaccination
Pediatrics, August 1, 2003; 112(2): e98 - 103.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
I. M. Gonzalez, F. M. Averhoff, M. S. Massoudi, H. Yusuf, F. DeStefano, P. Kramarz, J. E. Maher, J. P. Mullooly, C. Chun, R. L. Davis, et al.
Hepatitis B Vaccination Among Adolescents in 3 Large Health Maintenance Organizations
Pediatrics, November 1, 2002; 110(5): 929 - 934.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
Childhood Vaccines--United States, 1995-1999
JAMA, December 26, 2001; 286(24): 3073 - 3074.
[Full Text] [PDF]


Home page
Clin. Microbiol. Rev.Home page
P. H. Dennehy
Active Immunization in the United States: Developments over the Past Decade
Clin. Microbiol. Rev., October 1, 2001; 14(4): 872 - 908.
[Abstract] [Full Text] [PDF]


Home page
Arch Pediatr Adolesc MedHome page
H. A. McPhillips, R. L. Davis, E. K. Marcuse, and J. A. Taylor
The Rotavirus Vaccine's Withdrawal and Physicians' Trust in Vaccine Safety Mechanisms
Arch Pediatr Adolesc Med, September 1, 2001; 155(9): 1051 - 1056.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
W. E. Barlow, R. L. Davis, J. W. Glasser, P. H. Rhodes, R. S. Thompson, J. P. Mullooly, S. B. Black, H. R. Shinefield, J. I. Ward, S. M. Marcy, et al.
The Risk of Seizures after Receipt of Whole-Cell Pertussis or Measles, Mumps, and Rubella Vaccine
N. Engl. J. Med., August 30, 2001; 345(9): 656 - 661.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
W. A. Wattigney, G. T. Mootrey, M. M. Braun, and R. T. Chen
Surveillance for Poliovirus Vaccine Adverse Events, 1991 to 1998: Impact of a Sequential Vaccination Schedule of Inactivated Poliovirus Vaccine Followed by Oral Poliovirus Vaccine
Pediatrics, May 1, 2001; 107(5): 83e - 83.
[Abstract] [Full Text]


Home page
PediatricsHome page
M. M. Braun, G. T. Mootrey, M. E. Salive, R. T. Chen, S. S. Ellenberg, and the VAERS Working Group
Infant Immunization With Acellular Pertussis Vaccines in the United States: Assessment of the First Two Years' Data From the Vaccine Adverse Event Reporting System (VAERS)
Pediatrics, October 1, 2000; 106(4): 51e - 51.
[Abstract] [Full Text]


Home page
JAMAHome page
R. P. Wise, M. E. Salive, M. M. Braun, G. T. Mootrey, J. F. Seward, L. G. Rider, and P. R. Krause
Postlicensure Safety Surveillance for Varicella Vaccine
JAMA, September 13, 2000; 284(10): 1271 - 1279.
[Abstract] [Full Text] [PDF]


Home page
Arch Fam MedHome page
P. Kramarz, F. DeStefano, P. M. Gargiullo, R. L. Davis, R. T. Chen, J. P. Mullooly, S. B. Black, H. R. Shinefield, K. Bohlke, J. I. Ward, et al.
Does Influenza Vaccination Exacerbate Asthma?: Analysis of a Large Cohort of Children With Asthma
Arch Fam Med, July 1, 2000; 9(7): 617 - 623.
[Abstract] [Full Text] [PDF]


Home page
J. Epidemiol. Community HealthHome page
T. JEFFERSON
Real or perceived adverse effects of vaccines and the media---a tale of our times
J Epidemiol Community Health, June 1, 2000; 54(6): 402 - 403.
[Full Text] [PDF]


Home page
NEJMHome page
H. S. Izurieta, W. W. Thompson, P. Kramarz, D. K. Shay, R. L. Davis, F. DeStefano, S. Black, H. Shinefield, and K. Fukuda
Influenza and the Rates of Hospitalization for Respiratory Disease among Infants and Young Children
N. Engl. J. Med., January 27, 2000; 342(4): 232 - 239.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
R. L. Davis, D. Rubanowice, H. R. Shinefield, N. Lewis, D. Gu, S. B. Black, F. DeStefano, P. Gargiullo, J. P. Mullooly, R. S. Thompson, et al.
Immunization Levels Among Premature and Low-Birth-Weight Infants and Risk Factors for Delayed Up-to-Date Immunization Status
JAMA, August 11, 1999; 282(6): 547 - 553.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
The National Vaccine Advisory Committee
Strategies to Sustain Success in Childhood Immunizations
JAMA, July 28, 1999; 282(4): 363 - 370.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
Committee on Infectious Diseases, 1998MIHNEAndash1, Ex-Officio, and L. Representatives
Combination Vaccines for Childhood Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP)
Pediatrics, May 1, 1999; 103(5): 1064 - 1077.
[Full Text]


Home page
JAMAHome page
L. A. Jackson, P. Benson, V.-P. Sneller, J. C. Butler, R. S. Thompson, R. T. Chen, L. S. Lewis, G. Carlone, F. DeStefano, P. Holder, et al.
Safety of Revaccination With Pneumococcal Polysaccharide Vaccine
JAMA, January 20, 1999; 281(3): 243 - 248.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
T. Lasky, G. J. Terracciano, L. Magder, C. L. Koski, M. Ballesteros, D. Nash, S. Clark, P. Haber, P. D. Stolley, L. B. Schonberger, et al.
The Guillain-Barre Syndrome and the 1992-1993 and 1993-1994 Influenza Vaccines
N. Engl. J. Med., December 17, 1998; 339(25): 1797 - 1802.
[Abstract] [Full Text] [PDF]


Home page
Arch Pediatr Adolesc MedHome page
G. Evans
Vaccine Liability and Safety Revisited
Arch Pediatr Adolesc Med, January 1, 1998; 152(1): 7 - 10.
[Full Text] [PDF]


Home page
PediatricsHome page
R. L. Davis, E. M. MD, S. Black, H. Shinefield, B. Givens, J. Schwalbe, P. Ray, R. S. Thompson, R. Chen, and the Vaccine Safety Datalink Team
MMR2 Immunization at 4 to 5 Years and 10 to 12 Years of Age: A Comparison of Adverse Clinical Events After Immunization in the Vaccine Safety Datalink Project
Pediatrics, November 1, 1997; 100(5): 767 - 771.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Public HealthHome page
S. S. Ellenberg, M. A. Foulkes, K. Midthun, and K. L. Goldenthal
Evaluating the Safety of New Vaccines: Summary of a Workshop
Am J Public Health, May 1, 2005; 95(5): 800 - 807.
[Abstract] [Full Text] [PDF]